Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Manufacturers Try To Up Their Game As US Pressure Persists

Executive Summary

With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.

Advertisement

Related Content

After The Cliff: Fewer Patent Expiries Mean Less Savings From Generics
Generic Industry Consolidating But Still Mysterious
Can US FDA Save Pharma From Price Controls?
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
Mylan’s Generic Advair Delay Gives Leverage To Rivals
Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment
Teva Catches A Break On Copaxone 40mg, But For How Long?
Teva CEO Steps Down While An Integration Hangs In The Balance
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel